Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 13/20 | 0.71 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972544 | 1.00 | GRM4 (0.71) | GRM4GRM1CYP2C9 | |
| SCHEMBL1968923 | 0.83 | GRM4 (1.00) | GRM4GRM1CYP2C9 | |
| SCHEMBL1971777 | 0.81 | GRM4 (1.00) | GRM4GRM1CYP2C9 | |
| SCHEMBL1975043 | 0.81 | GRM4 (1.00) | GRM4GRM1CYP2C9 | |
| SCHEMBL1972220 | 0.78 | GRM4 (0.82) | GRM4GRM1CYP2C9 | |
| SCHEMBL1970530 | 0.77 | GRM4 (0.85) | GRM4GRM1 | |
| SCHEMBL12037587 | 0.77 | GRM4 (0.85) | GRM4GRM1CYP2C9 | |
| SCHEMBL1975901 | 0.77 | GRM4 (0.75) | GRM4GRM1CYP2C9 | |
| SCHEMBL1971131 | 0.75 | GRM4 (0.84) | GRM4GRM1CYP2C9 | |
| SCHEMBL1974371 | 0.74 | GRM4 (0.77) | GRM4GRM1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318266-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | claimed |
| EP-2334181-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | Merck Sharp & Dohme Corp. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010033349-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK & CO., INC. (US) | 2010-03-25 | — | — | WO | claimed |
| US-20110318266-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
| EP-2334181-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | Merck Sharp & Dohme Corp. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010033349-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | MERCK & CO., INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318266-A1 | PHTHALIMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS | GRM4, GRIA4, GRM1 | GRM4 1/4885GRM1 3/4885CYP2C9 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.